Feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus antibody responses in seronegative specific pathogen-free cats after a single administration of two different modified live FVRCP vaccines

Abstract

Two groups of feline panleukopenia virus (FPV), feline calicivirus (FCV), and feline herpesvirus-1 (FHV-1) seronegative cats (five cats per group) were administered one of two modified live feline viral rhinotracheitis, calicivirus, and panleukopenia virus (FVRCP) vaccines and the serological responses to each agent were followed over 28 days. While all cats developed detectable FPV and FCV antibody titers; only two cats developed detectable FHV-1 antibody titers using the criteria described by the testing laboratory. For FPV and FHV-1, there were no differences in seroconversion rates between the cats that were administered the intranasal (IN) FVRCP vaccine and the cats that were administered the parenteral FVRCP vaccine on any day post-inoculation. For FCV, the cats that were administered the IN FVRCP vaccine were more likely to seroconvert on days 10 and 14 when compared to cats that were administered the parenteral FVRCP vaccine.

Fig 1.

A positive result was defined by the laboratory performing the test as any HI titer>20. There were no significant differences in seroconversion rates on any day after inoculation. IN=UltraNasal FVRCP, Heska Corporation, Loveland, Colorado; SQ=Purevax Feline 3, Merial, Athens, Georgia.

Fig 2.

A positive result was defined by the laboratory performing the test as any SN titer>8. On the days marked *, a significantly greater number of cats administered the IN vaccine seroconverted. IN=UltraNasal FVRCP, Heska Corporation, Loveland, Colorado; SQ=Purevax Feline 3, Merial, Athens, Georgia.

Fig 3.

A positive result was defined by the laboratory performing the test as any SN titer>8. There were no significant differences in seroconversion rates on any day after inoculation. IN=UltraNasal FVRCP, Heska Corporation, Loveland, Colorado; SQ=Purevax Feline 3, Merial, Athens, Georgia.